CD274 and non-small cell lung carcinoma: Although durvalumab is a monoclonal antibody directed against the programmed death-ligand 1 (PD-L1), even NSCLC patients with a rather low tumoral PD-L1 expression benefit from durvalumab and the follow-up data of the PACIFIC trial confirm the overwhelming survival benefit across various patients [4–7].